Advertisement
Advertisement
RARE
Ultragenyx Pharmaceutical Inc.
25.83
USDSponsored
+0.51
+2.01%
Aug 21, 15:59 UTC -4
Closed
After-Market
25.98
+0.15
+0.58%
RARE Earnings Reports
Positive Surprise Ratio
RARE beat 21 of 43 last estimates.
49%
Next Report
Date of Next Report
Nov 02, 2026
Estimate for Q3 26 (Revenue/ EPS)
$189.09M
/-$1.09
Implied change from Q2 26 (Revenue/ EPS)
-11.64%
/+21.11%
Implied change from Q3 25 (Revenue/ EPS)
+18.23%
/-39.78%
Ultragenyx Pharmaceutical Inc. earnings per share and revenue
On Aug 04, 2026, RARE reported earnings of -0.90 USD per share (EPS) for Q2 26, beating the estimate of -1.23 USD, resulting in a 27.39% surprise. Revenue reached 214.00 million, compared to an expected 186.35 million, with a 14.84% difference. The market reacted with a -3.41% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 14 analysts forecast an EPS of -1.09 USD, with revenue projected to reach 189.09 million USD, implying an increase of 21.11% EPS, and decrease of -11.64% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Alvotech Ordinary Shares
Report Date
Aug 19, 2026 For Q2 26
Estimate
-$0.02
Actual
-$0.11
Surprise
-300.00%
CorMedix Inc.
Report Date
Aug 13, 2026 For Q2 26
Estimate
$0.24
Actual
$0.28
Surprise
+19.44%
Prenetics Global Limited Class A Ordinary Share
Report Date
Aug 18, 2026 For Q2 26
Estimate
-$0.71
Actual
-$0.53
Surprise
+26.30%
Fate Therapeutics, Inc.
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.27
Actual
-$0.25
Surprise
+8.49%
Alpha Cognition Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.40
Surprise
-0.05%
Caribou Biosciences, Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.32
Actual
-$0.24
Surprise
+25.74%
TuHURA Biosciences, Inc. Common Stock
Report Date
Aug 14, 2026 For Q2 26
Estimate
-$0.14
Actual
-$0.14
Surprise
+5.34%
Outlook Therapeutics, Inc. Common Stock
Report Date
Aug 14, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.09
Surprise
+5.46%
Elutia Inc. Class A Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.15
Actual
-$0.17
Surprise
-11.11%
Lantern Pharma Inc. Common Stock
Report Date
Aug 14, 2026 For Q2 26
Estimate
-$0.38
Actual
-$0.28
Surprise
+27.76%
FAQ
What were Ultragenyx Pharmaceutical Inc.'s earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Ultragenyx Pharmaceutical Inc. reported EPS of -$0.90, beating estimates by 27.39%, and revenue of $214.00M, 14.84% above expectations.
How did the market react to Ultragenyx Pharmaceutical Inc.'s Q2 2026 earnings?
The stock price moved down -3.41%, changed from $25.81 before the earnings release to $24.93 the day after.
When is Ultragenyx Pharmaceutical Inc. expected to report next?
The next earning report is scheduled for Nov 02, 2026.
What are the forecasts for Ultragenyx Pharmaceutical Inc.'s next earnings report?
Based on 14
analysts, Ultragenyx Pharmaceutical Inc. is expected to report EPS of -$1.09 and revenue of $189.09M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement